Why ADMA Biologics, Inc. (ADMA) Surged on Monday
The stock market kicked off the trading week on a mixed note, with two major indices ending in the green, as investors continued to digest more corporate earnings results.
Among the bellwether indices, only the Nasdaq ended in the red, dropping 0.10 percent. In contrast, the Dow Jones grew by 0.28 percent and the S&P 500 inched up by 0.06 percent.
Meanwhile, 10 companies mirrored a broader market optimism, as investors snapped up shares ahead of their first-quarter earnings performance in the next few days.
To come up with the list, we considered only the companies with a $2-billion market capitalization and $5-million trading volume.
An independent distributor in their pharmacy with a range of biopharmaceutical products on display.
ADMA Biologics, Inc. (NASDAQ:ADMA) soared to a new all-time high on Monday after securing the approval of the Food and Drug Administration (FDA) for its innovative yield enhancement production process.
According to the company, the innovative process has demonstrated an ability to increase production yields by approximately 20 percent from the same starting plasma volume.
Following the announcement, ADMA Biologics, Inc. (NASDAQ:ADMA) touched a new record high of $25.67 at intraday trading before early profit-taking pulled its price slightly lower to end the day just up by 12.12 percent at $24.51 apiece.
'This approval represents a pivotal milestone for ADMA, unlocking the opportunity for meaningful acceleration in our revenue and earnings trajectory beginning in late 2025 and accelerating further into 2026 and beyond,' said Adam Grossman, president and CEO of ADMA Biologics, Inc. (NASDAQ:ADMA).
'Looking ahead, we are excited to continue to advance our internal R&D platform—further optimizing production capabilities and progressing novel pipeline programs, most notably SG-001, our pre-clinical, investigative hyperimmune globulin targeting S. pneumonia, which exemplifies our commitment to product and process innovation,' he added.
Overall ADMA ranks 3rd on our list of the best performing stocks on Monday. While we acknowledge the potential of ADMA as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ADMA but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: and .
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
Think It's Too Late to Buy Rivian? Here's the No. 1 Reason Why There's Still Time.
Key Points Rivian's growth rates could spike next year. But the electric vehicle manufacturer still lacks one key growth driver. 10 stocks we like better than Rivian Automotive › Rivian Automotive (NASDAQ: RIVN) is about to enter one of the most exciting growth spurts in its history. It plans to launch a new discounted model in as little as six months, with two more new models to follow soon after. These launches could easily double or even triple the company's revenue over the coming years. That has investors excited and the stock price on the rise. Think it's too late to invest? Think again. There's one reason Rivian shares remain surprisingly cheap. Rivian doesn't have this exciting business segment Other electric vehicle stocks like Tesla and Lucid Group trade at 6 to 13 times trailing sales. Rivian, meanwhile, trades at just 2.6 times trailing sales. Why the big discount? Growth is a big part of the story. Lucid is expected to grow its sales by 60% this fiscal year, while Rivian's sales are expected to grow by just 6.5%. Tesla is the outlier. Analysts expect its sales to fall by around 5% this year. Why then does Tesla stock remain extremely expensive? It turns out that both Lucid and Tesla have a growth opportunity that Rivian hasn't pursued very aggressively: robotaxis. Robotaxis are expected to be a huge market. Some analysts think the global opportunity could eventually be worth up to $10 trillion. Recent robotaxi announcements from both Lucid and Tesla, therefore, have given investors plenty of optimism for long-term growth potential. Rivian has been surprisingly quiet on the robotaxi front. One of its board members even recently criticized Tesla's efforts, stressing that the service has a long way to go to be truly autonomous. A lack of robotaxi upside is likely a strong reason why Rivian shares are priced at such a relative discount to the competition. The robotaxi opportunity is still very early stages, however. Rivian's new models, meanwhile, are near-term opportunities. We should see growth rates pick up considerably next year, allowing investors to take advantage of today's discounted valuation. Rivian simply doesn't need robotaxis to grow considerably in 2025. Should you invest $1,000 in Rivian Automotive right now? Before you buy stock in Rivian Automotive, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Rivian Automotive wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $654,781!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,076,588!* Now, it's worth noting Stock Advisor's total average return is 1,055% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Ryan Vanzo has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Tesla. The Motley Fool has a disclosure policy. Think It's Too Late to Buy Rivian? Here's the No. 1 Reason Why There's Still Time. was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
3 minutes ago
- Business Wire
Circle Pharma Announces Publication in Nature Demonstrating Robust Pre-clinical Anti-tumor Activity of Cyclin A/B RxL Inhibition
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for difficult-to-treat cancers, today announced a Nature publication describing robust pre-clinical tumor suppression and novel mechanistic insights from inhibiting the binding of certain protein substrates (that bind via RxL motifs) to cyclins A and B in E2F-high tumor cells. Circle Pharma's oral cyclin A/B RxL inhibitor, CID-078, is a first-in-class, orally bioavailable macrocycle with dual cyclin A and B RxL inhibitory activity that is being evaluated in a Phase 1 clinical trial for patients with advanced solid tumors. Cyclins (including cyclins A and B) are a family of proteins that function as master regulators of the cell cycle by binding to and activating their catalytic partners, the cyclin-dependent kinases (CDKs). Cancers driven by high E2F activity, such as small cell lung cancer (SCLC) and other tumors with RB1 alterations, have an overactive cell cycle that leads to uncontrolled tumor cell proliferation. In preclinical models, cyclin A/B RxL inhibitors: Blocked the cyclin A-E2F interaction, triggering aberrant sustained E2F activity, DNA damage, and replication stress. Subsequently disrupted the cyclin B-Myt1 interaction, removing a critical safety brake and forcing damaged tumor cells through division, causing tumor cell death. Produced robust anti-tumor activity, including in chemotherapy-resistant SCLC patient-derived xenograft models. The publication, which was co-authored by scientists from Circle Pharma and the Dana-Farber Cancer Institute, Harvard Medical School, the University of Texas Southwestern Medical Center, and the University of Oxford, can be accessed here (doi: 10.1038/s41586-025-09433-w). 'We are excited to have the novel biology and compelling anti-cancer effects of the cyclin A/B RxL inhibitors developed at Circle recognized within the broader scientific community through this publication in Nature,' said David J. Earp, J.D., Ph.D., president and chief executive officer of Circle Pharma. 'This work underscores the capabilities of our MXMO™ platform to generate oral, cell-permeable macrocycle therapies, such as CID-078, including for historically undruggable targets such as cyclins. With our first-in-human Phase 1 study of CID-078 well underway, we are eager to see the innovative research outlined in this publication translate into new, high-impact therapeutic options for people living with cancer.' 'These findings build upon previous work and reveal additional gain-of-function mechanisms through which cyclin A/B RxL inhibition triggers apoptosis in cancer cells, further supporting this approach for E2F-driven cancers, such as cancers with RB1 alterations, which includes nearly all SCLCs, up to half of triple-negative breast cancers, and subsets of other solid tumors,' said Matthew G. Oser, M.D., Ph.D., senior author of the publication and associate professor of medicine at Dana-Farber Cancer Institute and Harvard Medical School. 'Circle Pharma's cell-permeable, oral macrocycles are designed to overcome the limitations of other therapeutic modalities and are ideally positioned to access cyclins and other historically undruggable targets, offering exciting potential for patients with cancer.' About CID-078, Circle Pharma's Oral Cyclin A/B RxL Inhibitor Program CID-078 is an orally bioavailable macrocycle with dual activity blocking protein-protein interactions between both cyclins A and B and key substrates that bind to them via conserved RxL motifs. CID-078 selectively targets tumor cells with oncogenic alterations that cause cell cycle dysregulation, including alterations in the tumor suppressor RB1. In pre-clinical studies, Circle Pharma's cyclin A/B RxL inhibitors have been shown to potently and selectively disrupt the protein-to-protein interaction between cyclins A and B and their key substrates and modulators, including E2F (a substrate of cyclin A) and MYT1 (a modulator of cyclin B). Preclinical studies have demonstrated the ability of these cyclin A/B RxL inhibitors to cause single-agent tumor regressions in multiple in vivo models. A multi-center Phase 1 clinical trial (NCT06577987) is currently enrolling patients with advanced solid tumors harboring RB1 alterations. About Circle Pharma Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop next-generation targeted therapies for cancer and other serious illnesses. The company's proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies, including for historically undruggable targets. Circle Pharma's pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. The company's lead program, CID-078, is a cyclin A/B RxL inhibitor in Phase 1 clinical development for patients with advanced solid tumors. Circle Pharma is based in South San Francisco, CA. For additional information, please visit us at and follow us on LinkedIn and X.
Business Insider
4 minutes ago
- Business Insider
'Big Short' investor Michael Burry has gone from bear to bull on stocks, portfolio gurus say
"The Big Short" made Michael Burry one of the market's most famous bears. But he seems to have warmed to stocks last quarter, three portfolio gurus told Business Insider. The investor's Scion Asset Management swapped out bearish put options on six stocks for bullish call options on nine stocks last quarter, its portfolio update from last week shows. The notional values of those positions were $186 million and $522 million, respectively. At the end of March, Burry's hedge fund held seven positions, including puts on Alibaba, and Nvidia, plus a direct stake in Estée Lauder, per its first-quarter portfolio update. Three months later, it held 15 positions, including calls and direct stakes in Estée Lauder and Lululemon, and calls on Alibaba, and VF. While these filings only capture a snapshot of Burry's US stock holdings on a single day and are published with a six-week delay, they may provide some insights into his investing strategy and market outlook. Burry bet against China-exposed tech stocks in Q1, but pivoted in Q2 Burry's first-quarter portfolio suggests he was confident that tech stocks, especially in China, would "suffer considerably going forward," Peter Mallouk, the president and CEO of Creative Planning, told Business Insider. "He clearly thought these stocks are overvalued and was expecting a correction — at least — in this group," he added. All of the stocks Burry bet against except Nvidia declined last quarter. Burry's revamped positions at the end of June "signal a very different take," Mallouk said, adding that the calls and long bets are "substantive" and indicate he's "expecting the run up to continue." "He has gone from a strong conviction bet on a sector fall to a broad-based bet the bull run will continue," Mallouk said. The benchmark S&P 500 index has surged more than 28% from its April low, and more than 3% since the end of June, to record highs of above 6,400 points. Burry didn't respond to a request for comment from Business Insider. Gerry Fowler, the head of equity derivatives at UBS, said that Burry seems to have swung from "modest bearishness to cautious bullishness." Burry's portfolio appears "opportunistic" and "contrarian," Fowler added, as he switched his short bets on China-exposed stocks such as Alibaba and to long wagers on those same names plus others that tanked in April. Fowler added that the size of Burry's long positions suggests he's not relying heavily on debt to finance them, and his call options "reflect some concern for downside risks still," because using options means tying up less capital and putting less money at risk than if he bought the underlying stocks. Burry appears to have bet on several embattled companies to stage comebacks, Daniel Bustamante, the chief investor of Bustamante Capital Management and founder of "The LongVol Report," told Business Insider. The fund manager said Estée Lauder and VF, the owner of The North Face, are "genuine turnaround plays" as the beauty giant's new CEO is working to cut costs and revitalize weak China sales, while the new bosses of VF are trying to revive its street-fashion brand Vans and cut costs too. Bustamante said he felt less positive about Burry's bullish position on athleisure brand Lululemon, which recently lost its chief product officer, Sun Choe, to VF. "Losing her is the equivalent to losing Steph Curry to another team," Bustamante said. The stock has tumbled nearly 50% this year as investors have balked at slowing growth, fierce competition, and tariffs raising its costs. Burry's use of options could result in a bigger payout By using options, Burry is "playing it in the right manner both from a risk perspective and potential return view," Bustamante said, as he stands to pocket an "asymmetric payout" if any of the ailing businesses do bounce back. Burry's iconic "Big Short" against the mid-2000s housing bubble was also asymmetric. He purchased credit-default swaps that acted as insurance against a housing crash, paid only modest premiums to hold them, then reaped huge profits when widespread mortgage defaults triggered payouts from the derivatives.
